| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/02/2013 | US20130108682 Wound care product comprising a cathelicidin polypeptide |
| 05/02/2013 | US20130108681 Injectable Depot Compositions and Uses Thereof |
| 05/02/2013 | US20130108680 Implantable tizanidine compositions and methods of treatment thereof |
| 05/02/2013 | US20130108675 Organic compounds |
| 05/02/2013 | US20130108672 Pharmaceutical compositions for substituted quinazolinones |
| 05/02/2013 | US20130108670 Compositions and methods for treating full thickness burn injuries |
| 05/02/2013 | US20130108668 Therapeutic Polymeric Nanoparticles Comprising Epothilone and Methods of Making and Using Same |
| 05/02/2013 | US20130108667 Method, apparatus and system for electroporation |
| 05/02/2013 | US20130108666 Glass/carbon nanotube composite material for bone graft support |
| 05/02/2013 | US20130108611 Fragmented polymeric compositions and methods for their use |
| 05/02/2013 | US20130108570 Antiperspirant Soft Solid Compositions Comprising A Wax Blend |
| 05/02/2013 | US20130108557 Cosmetic foam |
| 05/02/2013 | US20130108556 Pharmaceutical form for combating chemical submission of a medicament |
| 05/02/2013 | US20130108551 Lipid bilayer carrier for drugs or imaging agents |
| 05/02/2013 | US20130104881 Stabilized Metered Dose Inhaler |
| 05/02/2013 | DE102011117470A1 Method and composition of topical antiinflammatory plaster e.g. to accelerate wound healing comprises introducing sodium channel blocker from local ester/amide type anesthetics in skin adhesive area of plaster lying around wound dressing |
| 05/02/2013 | DE102011117421A1 Pharmaceutical composition useful for treating Lyme disease, comprises mixture of active substances including ceftriaxone and cefotaxime |
| 05/02/2013 | CA2853823A1 Protein formulations containing amino acids |
| 05/02/2013 | CA2853804A1 Anti-flush compositions |
| 05/02/2013 | CA2853701A1 Artemisinin and berberine compositions and methods of making |
| 05/02/2013 | CA2853472A1 Pharmaceutical composition and kit for treating bacterial infections |
| 05/02/2013 | CA2853347A1 Device and method for sustained release of therapeutic agent |
| 05/02/2013 | CA2853316A1 Limit size lipid nanoparticles and related methods |
| 05/02/2013 | CA2853277A1 Implantable drug delivery compositions and methods of treatment thereof |
| 05/02/2013 | CA2853251A1 Implantable rasagiline compositions and methods of treatment thereof |
| 05/02/2013 | CA2853249A1 Implantable tizanidine compositions and methods of treatment thereof |
| 05/02/2013 | CA2853117A1 Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof |
| 05/02/2013 | CA2853112A1 Antibody formulations and methods |
| 05/02/2013 | CA2852970A1 Novel dosage form |
| 05/02/2013 | CA2852536A1 Methods and compositions for treating pain |
| 05/02/2013 | CA2852114A1 Sweet tart energy tablet |
| 05/02/2013 | CA2851331A1 Improved cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus |
| 05/01/2013 | EP2586523A1 Process for producing emulsifier-producing material, process for producing emulsifier, emulsifier for orally administered composition, and orally administered composition |
| 05/01/2013 | EP2586464A1 Tolvaptan solid dispersion and its preparation method |
| 05/01/2013 | EP2586463A1 Pharmaceutical multimeric particles, and manufacturing method for same |
| 05/01/2013 | EP2586449A2 Lipid emulsion having krill oil as an active ingredient and preparation method therefor |
| 05/01/2013 | EP2586444A1 Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition |
| 05/01/2013 | EP2586437A1 Composition containing at least one nutritive, at least one disinfecting or decontaminating, and/or at least one protease-inhibiting active compound and/or active compound complex |
| 05/01/2013 | EP2586430A2 Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved |
| 05/01/2013 | EP2586429A1 Multi-unit drug delivery device for pulsatile or sustained release |
| 05/01/2013 | EP2586428A1 Manufacture of multiple minicapsules |
| 05/01/2013 | EP2586427A2 Balsalazide formulations and manufacture thereof |
| 05/01/2013 | EP2586426A1 Carboxyvinyl polymer-containing nanoparticle suspensions |
| 05/01/2013 | EP2586425A1 Preparing method of allicin injection and low temperature continuous stirring ultrafiltration device thereof |
| 05/01/2013 | EP2586424A1 New pharmaceutical combinations |
| 05/01/2013 | EP2585209A1 Method and device for producing vesicles |
| 05/01/2013 | EP2585182A1 Method of producing pharmacologically pure crystals |
| 05/01/2013 | EP2585111A1 Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent |
| 05/01/2013 | EP2585105A2 Treatment of sanfilippo syndrome type b |
| 05/01/2013 | EP2585104A2 Methods and compositions for cns delivery of arylsulfatase a |
| 05/01/2013 | EP2585103A1 Method of treatment |
| 05/01/2013 | EP2585092A1 Pharmaceutical composition containing goserelin for in-situ implant |
| 05/01/2013 | EP2585091A1 Sustained-release formulation |
| 05/01/2013 | EP2585090A1 Keloid treatment |
| 05/01/2013 | EP2585076A1 Dialysis precursor composition |
| 05/01/2013 | EP2585075A2 Methods of treatment for esophageal inflammation |
| 05/01/2013 | EP2585062A1 Injectable formulation of a macrocyclic lactone and levamisole |
| 05/01/2013 | EP2585056A2 Composition and method of treating lipid encapsulated virus infections |
| 05/01/2013 | EP2585053A2 Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
| 05/01/2013 | EP2585052A2 Controlled release compositions with reduced food effect |
| 05/01/2013 | EP2585051A2 Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| 05/01/2013 | EP2585050A1 Silodosin-cyclodextrin inclusion compounds |
| 05/01/2013 | EP2585049A1 Neramexane multiple unit dosage form |
| 05/01/2013 | EP2585048A1 Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| 05/01/2013 | EP2585047A1 Dry powder formulation comprising an antimuscarinic drug |
| 05/01/2013 | EP2585046A2 Lecithin carrier vesicles and methods of making the same |
| 05/01/2013 | EP2585045A2 Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations |
| 05/01/2013 | EP2585044A1 Long-term storage of non-glycosylated recombinant human g-csf |
| 05/01/2013 | EP2585043A2 A bioactive dose containing a material for modulating ph of a bodily fluid |
| 05/01/2013 | EP2585042A1 Stable formaldehyde-free microcapsules |
| 05/01/2013 | EP2585041A1 Taste-masked pharmaceutical formulation having accelerated onset of action |
| 05/01/2013 | EP2585040A1 Compositions and methods for enhancing reduction of spore-forming microorganism |
| 05/01/2013 | EP2585039A2 Dialysis precursor composition |
| 05/01/2013 | EP2585038A1 Pharmaceutical composition comprising midazolam |
| 05/01/2013 | EP2585037A1 Topical ophthalmic suspensions containing tobramycin and dexamethasone |
| 05/01/2013 | EP2585029A2 Dental care chewing gum comprising silver moieties |
| 05/01/2013 | EP2585025A1 Therapeutic oral composition |
| 05/01/2013 | EP2584915A1 Ingredient delivery system |
| 05/01/2013 | EP2584913A1 Stabilized active compound |
| 05/01/2013 | EP2584900A1 Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis |
| 05/01/2013 | CN202909137U Mastopathy external patch |
| 05/01/2013 | CN202909136U Transdermal patch with dense acupuncture micropores |
| 05/01/2013 | CN202909135U Medicine patch for curing foot calluses, cleft hands and cleft feet |
| 05/01/2013 | CN202909134U Film coated Bi-ke tablet |
| 05/01/2013 | CN202909133U Muscle and bone dieda pill |
| 05/01/2013 | CN202909115U Die for producing cyclosporine self-microemulsifying soft capsules |
| 05/01/2013 | CN103080313A Conjugates, particles, compositions, and related methods |
| 05/01/2013 | CN103079632A Intrauterine electronic capsule for administering a substance |
| 05/01/2013 | CN103079596A Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation |
| 05/01/2013 | CN103079595A Aqueous composition for ophthalmic administration |
| 05/01/2013 | CN103079592A Method for treating and diagnosing cancer by using cell-derived microvesicles |
| 05/01/2013 | CN103079559A Formulations including amiodarone and salts thereof and methods of their manufacture and use |
| 05/01/2013 | CN103079557A Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses |
| 05/01/2013 | CN103079552A Topical pharmaceutical composition comprising flurbiprofen |
| 05/01/2013 | CN103079549A Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) |
| 05/01/2013 | CN103079548A Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| 05/01/2013 | CN103079547A Process for producing drug-block-copolymer composite and pharmaceutical product containing same |
| 05/01/2013 | CN103079546A Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
| 05/01/2013 | CN103079545A Sulforaphane stabilization |
| 05/01/2013 | CN103079544A Injectable flowable composition comprising buprenorphine |